Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy

BACKGROUND: Immunosuppressive therapy of Graves’ orbitopathy (GO) is indicated during the active phase of disease. Intravenous steroids (IVGC) are effective in about 70% of patients, although unresponsiveness or relapse are observed. In previous studies, rituximab (RTX) has been shown to be effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Campi, Irene, Vannucchi, Guia, Muller, Ilaria, Lazzaroni, Elisa, Currò, Nicola, Dainese, Martina, Montacchini, Benedetta, Covelli, Danila, Guastella, Claudio, Pignataro, Lorenzo, Fugazzola, Laura, Arosio, Maura, Salvi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822584/
https://www.ncbi.nlm.nih.gov/pubmed/35145479
http://dx.doi.org/10.3389/fendo.2021.790246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822584/
https://www.ncbi.nlm.nih.gov/pubmed/35145479
http://dx.doi.org/10.3389/fendo.2021.790246

Ejemplares similares